Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 8 points (0.0%) at 17,140 as of Wednesday, Sept. 17, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,738 issues advancing vs. 1,242 declining with 174 unchanged. The Health Care sector currently sits up 0.6% versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include Baxter International ( BAX), down 2.8%, Gilead ( GILD), down 1.7%, DaVita HealthCare Partners ( DVA), down 1.3%, Medtronic ( MDT), down 0.9% and Covidien ( COV), down 0.9%. Top gainers within the sector include Auxilium Pharmaceuticals ( AUXL), up 44.2%, Endo International ( ENDP), up 6.7%, Alnylam Pharmaceuticals ( ALNY), up 4.8%, Abbott Laboratories ( ABT), up 1.3% and Sanofi ( SNY), up 1.2%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Smith & Nephew ( SNN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Smith & Nephew is down $1.19 (-1.4%) to $85.72 on heavy volume. Thus far, 113,399 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 142,200 shares. The stock has ranged in price between $85.04-$86.15 after having opened the day at $85.60 as compared to the previous trading day's close of $86.91. Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $15.7 billion and is part of the health services industry. Shares are up 21.1% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Smith & Nephew a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Smith & Nephew as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Smith & Nephew Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.